{"success":true,"data":{"pressRelease":{"id":"130986","rtpr_id":"nPn3t0VKca","ticker":"BLRX","exchange":"NASDAQ","all_tickers":["BLRX"],"title":"BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update","author":"PR Newswire","published_at":"2026-08-31T11:00:03.813Z","article_body":"BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update\n\nPR Newswire\n\nTEL AVIV, Israel, Aug. 31, 2026\n\n- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM;\nthird patient cohort expected to commence dosing in September -\n\n- Announced new data showing GLIX1 achieved potent antitumor activity in\nTMZ-resistant patient-derived xenograft (PDX) GBM in vivo model -\n\n- Announced additional data demonstrating strong synergistic effect between\nGLIX1 and PARP inhibitor in patient-derived HR-proficient ovarian cancer\nxenograft model -\n\n- Management to host conference call today, August 31, at 8:30 am EDT -\n\nTEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)\n(TASE: BLRX), a clinical-stage biopharmaceutical company pursuing\nlife-changing therapies in oncology and rare diseases, today reported its\nunaudited financial results for the quarter ended June 30, 2026, and provided\na corporate update.\n\n\"During the second quarter and subsequent period, we advanced GLIX1 across\nmultiple fronts,\" stated Philip Serlin, Chief Executive Officer of BioLineRx.\n\"Our Phase 1/2a study in glioblastoma is advancing as planned, with the second\ncohort in the Phase 1 part now being dosed, and the third cohort expected to\ncommence dosing in September. To date, a little more than four months into the\nstudy, we have been very pleased with the drug's safety and tolerability.\n\n\"Also, during the quarter, we were excited to demonstrate the potential of\nGLIX1 to address unmet needs for GBM as well as ovarian cancer in a number of\npre-clinical models. In this regard, we announced new data in a\ntemozolomide-resistant patient-derived xenograft (PDX) GBM in-vivo model,\nin which GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no\neffect. These results further support GLIX1's potential to treat a broad\nrange of patients with GBM. We also generated data showing strong synergy\nbetween GLIX1 and PARP inhibitors in an HR-proficient patient-derived ovarian\ncancer in-vivo model, and based upon these excellent findings, we are planning\nto add an ovarian cancer arm to the Phase 2a expansion phase of the trial.\nTogether, these developments keep GLIX1 on track in glioblastoma while\nextending its reach into additional tumor types where new treatment options\nare desperately needed.\"\n\nFinancial Updates\n\n * With $13.1 million on its balance sheet as of June 30, 2026, BioLineRx is\nmaintaining its cash runway guidance into the first half of 2027.\n * On August 27, 2026, the Company entered into a definitive agreement for an\noffering with gross proceeds of $3.75 million, expected to close on or about\nAugust 31, 2026.\nDevelopment Updates\n\nGLIX1 in GBM\n\n * In July, dosing commenced in the second of five planned cohorts in the Phase 1\ndose escalation part of the Phase 1/2a study.\n* Three leading cancer centers are enrolling patients in the Phase 1 part of\nthe\nstudy: NYU Langone Health, led by Dr. Alexandra Miller; Northwestern\nUniversity, led by Dr. Roger Stupp and Dr. Ditte Primdahl; and Moffit Cancer\nCenter, led by Dr. Patrick Grogan.\n * The Phase 1 part of the trial is expected to recruit up to 30 patients with\nrecurrent and progressive GBM and other high-grade gliomas. The objective is\nto establish a maximum tolerated dose (MTD) and/or a recommended dose based on\nsafety, PK/PD and preliminary efficacy.\n * The Phase 2a expansion part of the trial is planned to include various\npopulation cohorts, including GBM (newly diagnosed and/or recurrent), as well\nas additional cancers with/without standard of care (e.g., PARP inhibitors),\nincluding an ovarian cancer arm. These cohorts are expected to identify\npreliminary efficacy, PD assessments and dose optimization data, serving as\nthe basis for rapid and effective advanced clinical development.\n * New data\n(https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-announce-new-glix1-data-demonstrating)\n\ndemonstrated potent anti-tumor effect of GLIX1 in GBM across multiple in-vivo\nstudies, including a temozolomide (TMZ)-resistant patient-derived xenograft\nmodel. In the three orthotopic CDX studies, significant tumor growth\ninhibition and survival benefit were observed following treatment with GLIX1\nacross all doses tested, with greater benefit at higher dose levels. Most\nnotably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor\neffect while TMZ showed no effect.\n * Clinical and pre-clinical data have been accepted for publication at the\nEuropean Association of Neuro-Oncology (https://www.eano.eu/)\n(EANO) 2026 Conference and at the Society for Neuro-Oncology (SNO) 2026 Annual\nMeeting.\nGLIX1 in combination with PARPi\n\n * New data\n(https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-announce-new-preclinical-data)\n\ndemonstrated strong synergy between GLIX1 and PARP inhibitors, reinforcing\nsynthetic lethality between GLIX1 and PARP inhibitors.\n* Synergy was demonstrated in a patient-derived xenograft (PDX) in-vivo model\nof\nHR-proficient ovarian cancer, where PARP inhibitors have historically had\nlimited efficacy. Results show substantially better efficacy in the\ncombination arm versus the control arm and versus the monotherapy arms,\ndespite using lower doses in the combination arm. Notably, the low-dose\nGLIX1/olaparib combination tumor reduction was similar to cisplatin, the\ncurrent chemotherapy benchmark.\n * An\nabstract\n(https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-present-data-demonstrating-strong)\n\nfeaturing new GLIX1 data, demonstrating synergy with PARP inhibitors in\nHR-proficient ovarian cancer, was accepted for publication at the 2026\nEuropean Society for Medical Oncology Annual Congress (ESMO 2026) in October.\n * BioLineRx has initiated discussions with leading PARP inhibitor companies to\nexplore potential development collaborations.\nMotixafortide\n\nPancreatic Ductal Adenocarcinoma (mPDAC)\n\n * Enrollment is continuing in the CheMo4METPANC Phase 2b clinical trial, which\nis being led by Columbia University, and supported by both Regeneron and\nBioLineRx. The trial is evaluating motixafortide in combination with the PD-1\ninhibitor cemiplimab and standard chemotherapy (gemcitabine and\nnab-paclitaxel).\n* A prespecified interim/futility analysis is planned when 40% of\nprogression-free survival (PFS) events are observed, which the Company\ncontinues to anticipate will occur in 2026.\nAPHEXDA Performance Update\n\n * For the second quarter of 2026, APHEXDA sales were $1.6 million, which\nprovided royalty revenue to the Company of $0.3 million.\nFinancial Results for the Quarter ended June 30, 2026\n\n * Revenues for the three months ended June 30, 2026 were $0.3 million, similar\nto the three months ended June 30, 2025.\n * Research and development expenses for the three months ended June 30, 2026\nwere $2.9 million, an increase of $0.6 million, or 26.5%, compared to $2.3\nmillion for the comparable 2025 period. The increase resulted primarily from\nexpenses related to the new GLIX1 project, offset by lower expenses related to\nmotixafortide.\n * General and administrative expenses for the three months ended June 30, 2026\nwere $0.9 million, an increase of $0.7 million, or 313.9%, compared to $0.2\nmillion for the comparable 2025 period. The increase resulted from the\nreversal of a $0.8 million provision for doubtful accounts in the 2025 period\nfollowing receipt of an overdue milestone payment from Gloria.\n * Non-operating expenses amounted to $0.7 million for the three months ended\nJune 30, 2026, compared to non-operating expenses of $1.9 million for the\nthree months ended June 30, 2025. Non-operating expenses for both periods\nprimarily relates to fair-value adjustments of warrant liabilities on the\nCompany's balance sheet.\n * Net financial expenses for the three months ended June 30, 2026 were $0.1\nmillion compared to net financial income of $0.2 million for the three months\nended June 30, 2025. Net financial expenses in 2026 primarily relate to\ninterest paid on loans, partially offset by investment income earned on bank\ndeposits. Net financial income in 2025 primarily relates to investment income\nearned on bank deposits and gains on foreign currency cash balances due to the\nstrengthening of the NIS during the period, partially offset by interest paid\non loans.\n * Net loss for the three months ended June 30, 2026 was $4.3 million, compared\nto $3.9 million for the three months ended June 30, 2025.\n * As of June 30, 2026, the Company had cash, cash equivalents, and short-term\nbank deposits of $13.1 million.\nConference Call and Webcast Information\n\nTo access the conference call, please dial +1-888-407-2553 from the U.S. or\n+972-3-918-0685 internationally. A live webcast and a replay of the call can\nbe accessed through the event page\n(https://ir.biolinerx.com/events/event-details/biolinerx-report-second-quarter-2026-results-august-31-2026)\n on the Company's website. Please allow extra time prior to the call to visit\nthe site and download any necessary software to listen to the live broadcast.\nThe call replay will be available approximately two hours after completion of\nthe live conference call. A dial-in replay of the call will be available\nuntil September 1, 2026; please dial +1-888-295-2634 from the US or\n+972-3-925-5904 internationally.\n\nAbout BioLineRx\n\nBioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing\nlife-changing therapies in oncology and rare diseases. The Company's lead\ndevelopment asset is GLIX1, a first-in-class, oral, small molecule targeting\nDNA damage response in glioblastoma and other solid tumors, for which a Phase\n1/2a clinical trial was initiated in the first quarter of 2026. GLIX1 is being\ndeveloped under a collaboration with Hemispherian AS.\n\nThe Company's first approved product, APHEXDA® (motixafortide), is indicated\nin the U.S. for stem cell mobilization for autologous transplantation in\nmultiple myeloma, and is being commercialized by Ayrmid Ltd. (globally,\nexcept Asia) and by Gloria Biosciences (in Asia). BioLineRx has retained\nthe rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and\nhas a Phase 2b PDAC trial currently ongoing under a collaboration\nwith Columbia University.\n\n \n\nLearn more about who we are, what we do, and how we do it\nat www.biolinerx.com (http://www.biolinerx.com/) , or on LinkedIn\n(https://www.linkedin.com/company/112275/admin/) .\n\nForward Looking Statement\n\nVarious statements in this release concerning BioLineRx's future expectations\nconstitute \"forward-looking statements\" within the meaning of the Private\nSecurities Litigation Reform Act of 1995. These statements include words such\nas \"anticipates,\" \"believes,\" \"could,\" \"estimates,\" \"expects,\" \"intends,\"\n\"may,\" \"plans,\" \"potential,\" \"predicts,\" \"projects,\" \"should,\" \"will,\" and\n\"would,\" and describe opinions about future events. These include statements\nregarding management's expectations, beliefs and intentions regarding, among\nother things, the expectations with regard to the Phase 1/2a GLIX1 clinical\ntrial, expected timing of a clinical dosing, and BioLineRx's business\nstrategy. These forward-looking statements involve known and unknown risks,\nuncertainties and other factors that may cause the actual results, performance\nor achievements of BioLineRx to be materially different from any future\nresults, performance or achievements expressed or implied by such\nforward-looking statements. Factors that could cause BioLineRx's actual\nresults to differ materially from those expressed or implied in such\nforward-looking statements include, but are not limited to: the clinical\ndevelopment, commercialization and market acceptance of GLIX1 and\nmotixafortide including the degree and pace of market uptake of APHEXDA for\nthe mobilization of hematopoietic stem cells for autologous transplantation in\nmultiple myeloma patients; the initiation, timing, progress and results of\nBioLineRx's preclinical studies, clinical trials and other therapeutic\ncandidate development efforts; BioLineRx's ability to advance GLIX1 and\nmotixafortide into clinical trials or to successfully complete its preclinical\nstudies or clinical trials; whether the clinical trial results for GLIX1 and\nmotixafortide will be predictive of real-world results; BioLineRx's receipt of\nregulatory approvals for GLIX1 and motixafortide and the timing of other\nregulatory filings and approvals; whether access to GLIX1 and motixafortide is\nachieved in a commercially viable manner and whether GLIX1 and motixafortide\nreceives adequate reimbursement from third.-party payors; BioLineRx's ability\nto establish, manage, and maintain corporate collaborations, as well as the\nability of BioLineRx's collaborators to execute on their development and\ncommercialization plans; BioLineRx's ability to integrate new therapeutic\ncandidates and new personnel, as well as new collaborations; the\ninterpretation of the properties and characteristics of BioLineRx's\ntherapeutic candidates and of the results obtained with its therapeutic\ncandidates in preclinical studies or clinical trials; the implementation of\nBioLineRx's business model and strategic plans for its business and\ntherapeutic candidates; the scope of protection that BioLineRx's is able to\nestablish and maintain for intellectual property rights covering its\ntherapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; estimates of\nBioLineRx's expenses, future revenues, capital requirements and its need for\nand ability to access sufficient additional financing; risks related to\nchanges in healthcare laws, rules and regulations in the United States or\nelsewhere; competitive companies, technologies and BioLineRx's industry;\nBioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements\nas to the impact of the political and security situation in Israel on\nBioLineRx's business which may exacerbate the magnitude of the factors\ndiscussed above. These and other factors are more fully discussed in the \"Risk\nFactors\" section of BioLineRx's most recent annual report on Form 20-F filed\nwith the Securities and Exchange Commission on March 23, 2026. In addition,\nany forward-looking statements represent BioLineRx's views only as of the date\nof this release and should not be relied upon as representing its views as of\nany subsequent date. BioLineRx does not assume any obligation to update any\nforward-looking statements unless required by law.\n\nContacts:\n\nUnited States\nChuck Padala\nLifeSci Advisors, LLC\nIR@biolinerx.com (mailto:IR@biolinerx.com)\n\nIsrael\nMoran Meir\nLifeSci Advisors, LLC\nmoran@lifesciadvisors.com (mailto:moran@lifesciadvisors.com)\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION\n\n(UNAUDITED)\n\n December 31, June 30,\n 2025 2026\n in USD thousands\n Assets\n CURRENT ASSETS\n Cash and cash equivalents 3,250 4,627\n Short-term bank deposits 17,626 8,451\n Prepaid expenses 201 376\n Other receivables 456 728\n Inventory 2,148 2,167\n Total current assets 23,681 16,349\n\n NON-CURRENT ASSETS\n Property and equipment, net 160 130\n Right-of-use assets, net 696 673\n Intangible assets, net 16,368 16,328\n Total non-current assets 17,224 17,131\n Total assets 40,905 33,480\n\n Liabilities and equity\n CURRENT LIABILITIES\n Current maturities of long-term loan 4,479 4,479\n Accounts payable and accruals:\n Trade 3,493 4,294\n Other 1,743 2,206\n Current maturities of lease liabilities 234 280\n Warrants 2,174 2,420\n Total current liabilities 12,123 13,679\n\n NON-CURRENT LIABILITIES\n Long-term loan, net of current maturities 4,460 2,220\n Lease liabilities 977 962\n Total non-current liabilities 5,437 3,182\n\n COMMITMENTS AND CONTINGENT LIABILITIES\n Total liabilities 17,560 16,861\n\n EQUITY\n Equity attributable to owners of the Company:\n Ordinary shares 73,428 73,776\n Share premium 327,584 327,928\n Warrants 3,686 3,686\n Capital reserve 15,916 15,425\n Other comprehensive loss (1,416) (1,416)\n Accumulated deficit (401,002) (405,629)\n Total equity attributable to owners of the Company 18,196 13,770\n Non-controlling 5,149 2,849\n interest\n Total equity 23,345 16,619\n Total liabilities and equity 40,905 33,480\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)\n\n(UNAUDITED)\n\n Three months ended June 30, Six months ended June 30,\n 2025 2026 2025 2026\n in USD thousands in USD thousands\n\n ROYALTY REVENUES 304 294 559 771\n COST OF REVENUES (72) (59) (106) (154)\n GROSS PROFIT 232 235 453 617\n RESEARCH AND DEVELOPMENT EXPENSES (2,326) (2,943) (3,949) (5,471)\n GENERAL AND ADMINISTRATIVE EXPENSES (209) (865) (1,198) (1,723)\n OPERATING LOSS (2,303) (3,573) (4,694) (6,577)\n NON-OPERATING INCOME (EXPENSES), NET (1,851) (690) 5,793 (232)\n FINANCIAL INCOME 490 132 784 340\n FINANCIAL EXPENSES (276) (208) (696) (458)\n\n NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (3,940) (4,339) 1,187 (6,927)\n\n ATTRIBUTION OF NET INCOME (LOSS) AND\n COMPREHENSIVE INCOME (LOSS)\n To owners of the Company (3,940) (3,026) 1,187 (4,627)\n To non-controlling interests - (1,313) - (2,300)\n (3,940) (4,339) 1,187 (6,927)\n\n in USD in USD\n EARNINGS (LOSS) PER ORDINARY SHARE – BASIC AND (0.00) (0.00) 0.00 (0.00)\n DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY\n\n WEIGHTED AVERAGE NUMBER OF SHARES USED IN 2,369,687,536 2,664,807,584 2,294,127,662 2,662,530,811\n CALCULATION OF BASIC AND DILUTED EARNINGS\n (LOSS) PER ORDINARY SHARE\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY\n\n(UNAUDITED)\n\n Equity attributable to owners of the Company\n Ordinary shares Share Warrants Capital Other Accumulated Non- Total\n premium reserve comprehensive deficit controlling\n loss interest\n in shares 000's in USD thousands\n BALANCE AT JANUARY 1, 2025 1,336,670 38,097 353,693 5,367 17,547 (1,416) (399,827) - 13,461\n CHANGES FOR SIX MONTHS\n ENDED JUNE 30, 2025:\n Issuance of share capital, pre-funded 925,137 25,664 (20,988) 501 - - - - 5,177\n warrants and warrants, net\n Pre-funded warrants exercised 295,804 8,058 (5,876) (2,182) - - - - -\n Employee stock options expired - - 646 - (646) - - - -\n Share-based compensation - - - - 247 - - - 247\n Comprehensive income for the period - - - - - - 1,187 - 1,187\n BALANCE AT JUNE 30, 2025 2,557,611 71,819 327,475 3,686 17,148 (1,416) (398,640) - 20,072\n\n Equity attributable to owners of the Company\n Ordinary shares Share Warrants Capital Other Accumulated Non- Total\n premium reserve comprehensive deficit controlling\n loss interest\n in shares 000's in USD thousands\n BALANCE AT JANUARY 1, 2026 2,610,814 73,428 327,584 3,686 15,916 (1,416) (401,002) 5,149 23,345\n CHANGES FOR SIX MONTHS\n ENDED JUNE 30, 2026:\n Issuance of share capital 10,163 348 (304) - - - - - 44\n Employee stock options expired - - 648 - (648) - - - -\n Share-based compensation - - - - 157 - - - 157\n Comprehensive loss for the period - - - - - - (4,627) (2,300) (6,927)\n BALANCE AT JUNE 30, 2026 2,620,977 73,776 327,928 3,686 15,425 (1,416) (405,629) 2,849 16,619\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS\n\n(UNAUDITED)\n\n Six months ended June 30,\n 2025 2026\n in USD thousands\n CASH FLOWS - OPERATING ACTIVITIES\n Comprehensive income (loss) for the period 1,187 (6,927)\n Adjustments required to reflect net cash used in operating activities (3,955) 1,430\n (see appendix below)\n Net cash used in operating activities (2,768) (5,497)\n\n CASH FLOWS - INVESTING ACTIVITIES\n Investments in short-term deposits (24,818) (7,663)\n Maturities of short-term deposits 12,926 16,714\n Proceeds from sale of property and equipment 11 -\n Net cash provided by (used in) investing activities (11,881) 9,051\n\n CASH FLOWS - FINANCING ACTIVITIES\n Issuance of share capital and warrants, net of issuance costs 13,554 44\n Repayments of loan (2,240) (2,240)\n Repayments of lease liabilities (262) (124)\n Net cash provided by (used in) financing activities 11,052 (2,320)\n\n INCREASE )DECREASE( IN CASH AND CASH EQUIVALENTS (3,597) 1,234\n CASH AND CASH EQUIVALENTS - BEGINNING 10,436 3,250\n\n  OF PERIOD\n EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS 350 143\n CASH AND CASH EQUIVALENTS - END OF PERIOD 7,189 4,627\n\n \n\n \n\n BioLineRx Ltd.\n\nAPPENDIX TO CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS\n\n(UNAUDITED)\n\n Six months ended June 30,\n 2025 2026\n in USD thousands\n APPENDIX\n\n Adjustments required to reflect net cash used in operating\n activities:\n Income and expenses not involving cash flows:\n Depreciation and amortization 341 166\n Exchange differences on cash and cash equivalents (350) (143)\n Fair value adjustments of warrants (6,410) 246\n Share-based compensation 247 157\n Interest and exchange differences on short-term deposits 48 124\n Warrant issuance costs 702 -\n Exchange differences on lease liabilities 110 82\n (5,312) 632\n\n Changes in operating asset and liability items:\n Decrease in trade receivables 2,398 -\n Decrease (increase) in prepaid expenses and other receivables 1,146 (447)\n Decrease (increase) in inventory 295 (19)\n Increase (decrease) in accounts payable and accruals (2,482) 1,264\n 1,357 798\n (3,955) 1,430\n\n Supplemental information on interest received in cash 583 463\n Supplemental information on interest paid in cash 694 467\n Supplemental information on non-cash transactions:\n Changes in right-of-use asset and lease liabilities 45 73\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html\n(https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html)\n\nSOURCE BioLineRx Ltd.\n\n\n\n+972-8-6429100\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1457856/BioLineRx-Ltd-Logo.jpg?id=OA2919214\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3t0VKca","title":"BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update","author":"PR Newswire","ticker":"BLRX","created":"2026-08-31T11:00:03.813Z","tickers":["BLRX"],"exchange":"NASDAQ","article_body":"BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update\n\nPR Newswire\n\nTEL AVIV, Israel, Aug. 31, 2026\n\n- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM;\nthird patient cohort expected to commence dosing in September -\n\n- Announced new data showing GLIX1 achieved potent antitumor activity in\nTMZ-resistant patient-derived xenograft (PDX) GBM in vivo model -\n\n- Announced additional data demonstrating strong synergistic effect between\nGLIX1 and PARP inhibitor in patient-derived HR-proficient ovarian cancer\nxenograft model -\n\n- Management to host conference call today, August 31, at 8:30 am EDT -\n\nTEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)\n(TASE: BLRX), a clinical-stage biopharmaceutical company pursuing\nlife-changing therapies in oncology and rare diseases, today reported its\nunaudited financial results for the quarter ended June 30, 2026, and provided\na corporate update.\n\n\"During the second quarter and subsequent period, we advanced GLIX1 across\nmultiple fronts,\" stated Philip Serlin, Chief Executive Officer of BioLineRx.\n\"Our Phase 1/2a study in glioblastoma is advancing as planned, with the second\ncohort in the Phase 1 part now being dosed, and the third cohort expected to\ncommence dosing in September. To date, a little more than four months into the\nstudy, we have been very pleased with the drug's safety and tolerability.\n\n\"Also, during the quarter, we were excited to demonstrate the potential of\nGLIX1 to address unmet needs for GBM as well as ovarian cancer in a number of\npre-clinical models. In this regard, we announced new data in a\ntemozolomide-resistant patient-derived xenograft (PDX) GBM in-vivo model,\nin which GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no\neffect. These results further support GLIX1's potential to treat a broad\nrange of patients with GBM. We also generated data showing strong synergy\nbetween GLIX1 and PARP inhibitors in an HR-proficient patient-derived ovarian\ncancer in-vivo model, and based upon these excellent findings, we are planning\nto add an ovarian cancer arm to the Phase 2a expansion phase of the trial.\nTogether, these developments keep GLIX1 on track in glioblastoma while\nextending its reach into additional tumor types where new treatment options\nare desperately needed.\"\n\nFinancial Updates\n\n * With $13.1 million on its balance sheet as of June 30, 2026, BioLineRx is\nmaintaining its cash runway guidance into the first half of 2027.\n * On August 27, 2026, the Company entered into a definitive agreement for an\noffering with gross proceeds of $3.75 million, expected to close on or about\nAugust 31, 2026.\nDevelopment Updates\n\nGLIX1 in GBM\n\n * In July, dosing commenced in the second of five planned cohorts in the Phase 1\ndose escalation part of the Phase 1/2a study.\n* Three leading cancer centers are enrolling patients in the Phase 1 part of\nthe\nstudy: NYU Langone Health, led by Dr. Alexandra Miller; Northwestern\nUniversity, led by Dr. Roger Stupp and Dr. Ditte Primdahl; and Moffit Cancer\nCenter, led by Dr. Patrick Grogan.\n * The Phase 1 part of the trial is expected to recruit up to 30 patients with\nrecurrent and progressive GBM and other high-grade gliomas. The objective is\nto establish a maximum tolerated dose (MTD) and/or a recommended dose based on\nsafety, PK/PD and preliminary efficacy.\n * The Phase 2a expansion part of the trial is planned to include various\npopulation cohorts, including GBM (newly diagnosed and/or recurrent), as well\nas additional cancers with/without standard of care (e.g., PARP inhibitors),\nincluding an ovarian cancer arm. These cohorts are expected to identify\npreliminary efficacy, PD assessments and dose optimization data, serving as\nthe basis for rapid and effective advanced clinical development.\n * New data\n(https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-announce-new-glix1-data-demonstrating)\n\ndemonstrated potent anti-tumor effect of GLIX1 in GBM across multiple in-vivo\nstudies, including a temozolomide (TMZ)-resistant patient-derived xenograft\nmodel. In the three orthotopic CDX studies, significant tumor growth\ninhibition and survival benefit were observed following treatment with GLIX1\nacross all doses tested, with greater benefit at higher dose levels. Most\nnotably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor\neffect while TMZ showed no effect.\n * Clinical and pre-clinical data have been accepted for publication at the\nEuropean Association of Neuro-Oncology (https://www.eano.eu/)\n(EANO) 2026 Conference and at the Society for Neuro-Oncology (SNO) 2026 Annual\nMeeting.\nGLIX1 in combination with PARPi\n\n * New data\n(https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-announce-new-preclinical-data)\n\ndemonstrated strong synergy between GLIX1 and PARP inhibitors, reinforcing\nsynthetic lethality between GLIX1 and PARP inhibitors.\n* Synergy was demonstrated in a patient-derived xenograft (PDX) in-vivo model\nof\nHR-proficient ovarian cancer, where PARP inhibitors have historically had\nlimited efficacy. Results show substantially better efficacy in the\ncombination arm versus the control arm and versus the monotherapy arms,\ndespite using lower doses in the combination arm. Notably, the low-dose\nGLIX1/olaparib combination tumor reduction was similar to cisplatin, the\ncurrent chemotherapy benchmark.\n * An\nabstract\n(https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-present-data-demonstrating-strong)\n\nfeaturing new GLIX1 data, demonstrating synergy with PARP inhibitors in\nHR-proficient ovarian cancer, was accepted for publication at the 2026\nEuropean Society for Medical Oncology Annual Congress (ESMO 2026) in October.\n * BioLineRx has initiated discussions with leading PARP inhibitor companies to\nexplore potential development collaborations.\nMotixafortide\n\nPancreatic Ductal Adenocarcinoma (mPDAC)\n\n * Enrollment is continuing in the CheMo4METPANC Phase 2b clinical trial, which\nis being led by Columbia University, and supported by both Regeneron and\nBioLineRx. The trial is evaluating motixafortide in combination with the PD-1\ninhibitor cemiplimab and standard chemotherapy (gemcitabine and\nnab-paclitaxel).\n* A prespecified interim/futility analysis is planned when 40% of\nprogression-free survival (PFS) events are observed, which the Company\ncontinues to anticipate will occur in 2026.\nAPHEXDA Performance Update\n\n * For the second quarter of 2026, APHEXDA sales were $1.6 million, which\nprovided royalty revenue to the Company of $0.3 million.\nFinancial Results for the Quarter ended June 30, 2026\n\n * Revenues for the three months ended June 30, 2026 were $0.3 million, similar\nto the three months ended June 30, 2025.\n * Research and development expenses for the three months ended June 30, 2026\nwere $2.9 million, an increase of $0.6 million, or 26.5%, compared to $2.3\nmillion for the comparable 2025 period. The increase resulted primarily from\nexpenses related to the new GLIX1 project, offset by lower expenses related to\nmotixafortide.\n * General and administrative expenses for the three months ended June 30, 2026\nwere $0.9 million, an increase of $0.7 million, or 313.9%, compared to $0.2\nmillion for the comparable 2025 period. The increase resulted from the\nreversal of a $0.8 million provision for doubtful accounts in the 2025 period\nfollowing receipt of an overdue milestone payment from Gloria.\n * Non-operating expenses amounted to $0.7 million for the three months ended\nJune 30, 2026, compared to non-operating expenses of $1.9 million for the\nthree months ended June 30, 2025. Non-operating expenses for both periods\nprimarily relates to fair-value adjustments of warrant liabilities on the\nCompany's balance sheet.\n * Net financial expenses for the three months ended June 30, 2026 were $0.1\nmillion compared to net financial income of $0.2 million for the three months\nended June 30, 2025. Net financial expenses in 2026 primarily relate to\ninterest paid on loans, partially offset by investment income earned on bank\ndeposits. Net financial income in 2025 primarily relates to investment income\nearned on bank deposits and gains on foreign currency cash balances due to the\nstrengthening of the NIS during the period, partially offset by interest paid\non loans.\n * Net loss for the three months ended June 30, 2026 was $4.3 million, compared\nto $3.9 million for the three months ended June 30, 2025.\n * As of June 30, 2026, the Company had cash, cash equivalents, and short-term\nbank deposits of $13.1 million.\nConference Call and Webcast Information\n\nTo access the conference call, please dial +1-888-407-2553 from the U.S. or\n+972-3-918-0685 internationally. A live webcast and a replay of the call can\nbe accessed through the event page\n(https://ir.biolinerx.com/events/event-details/biolinerx-report-second-quarter-2026-results-august-31-2026)\n on the Company's website. Please allow extra time prior to the call to visit\nthe site and download any necessary software to listen to the live broadcast.\nThe call replay will be available approximately two hours after completion of\nthe live conference call. A dial-in replay of the call will be available\nuntil September 1, 2026; please dial +1-888-295-2634 from the US or\n+972-3-925-5904 internationally.\n\nAbout BioLineRx\n\nBioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing\nlife-changing therapies in oncology and rare diseases. The Company's lead\ndevelopment asset is GLIX1, a first-in-class, oral, small molecule targeting\nDNA damage response in glioblastoma and other solid tumors, for which a Phase\n1/2a clinical trial was initiated in the first quarter of 2026. GLIX1 is being\ndeveloped under a collaboration with Hemispherian AS.\n\nThe Company's first approved product, APHEXDA® (motixafortide), is indicated\nin the U.S. for stem cell mobilization for autologous transplantation in\nmultiple myeloma, and is being commercialized by Ayrmid Ltd. (globally,\nexcept Asia) and by Gloria Biosciences (in Asia). BioLineRx has retained\nthe rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and\nhas a Phase 2b PDAC trial currently ongoing under a collaboration\nwith Columbia University.\n\n \n\nLearn more about who we are, what we do, and how we do it\nat www.biolinerx.com (http://www.biolinerx.com/) , or on LinkedIn\n(https://www.linkedin.com/company/112275/admin/) .\n\nForward Looking Statement\n\nVarious statements in this release concerning BioLineRx's future expectations\nconstitute \"forward-looking statements\" within the meaning of the Private\nSecurities Litigation Reform Act of 1995. These statements include words such\nas \"anticipates,\" \"believes,\" \"could,\" \"estimates,\" \"expects,\" \"intends,\"\n\"may,\" \"plans,\" \"potential,\" \"predicts,\" \"projects,\" \"should,\" \"will,\" and\n\"would,\" and describe opinions about future events. These include statements\nregarding management's expectations, beliefs and intentions regarding, among\nother things, the expectations with regard to the Phase 1/2a GLIX1 clinical\ntrial, expected timing of a clinical dosing, and BioLineRx's business\nstrategy. These forward-looking statements involve known and unknown risks,\nuncertainties and other factors that may cause the actual results, performance\nor achievements of BioLineRx to be materially different from any future\nresults, performance or achievements expressed or implied by such\nforward-looking statements. Factors that could cause BioLineRx's actual\nresults to differ materially from those expressed or implied in such\nforward-looking statements include, but are not limited to: the clinical\ndevelopment, commercialization and market acceptance of GLIX1 and\nmotixafortide including the degree and pace of market uptake of APHEXDA for\nthe mobilization of hematopoietic stem cells for autologous transplantation in\nmultiple myeloma patients; the initiation, timing, progress and results of\nBioLineRx's preclinical studies, clinical trials and other therapeutic\ncandidate development efforts; BioLineRx's ability to advance GLIX1 and\nmotixafortide into clinical trials or to successfully complete its preclinical\nstudies or clinical trials; whether the clinical trial results for GLIX1 and\nmotixafortide will be predictive of real-world results; BioLineRx's receipt of\nregulatory approvals for GLIX1 and motixafortide and the timing of other\nregulatory filings and approvals; whether access to GLIX1 and motixafortide is\nachieved in a commercially viable manner and whether GLIX1 and motixafortide\nreceives adequate reimbursement from third.-party payors; BioLineRx's ability\nto establish, manage, and maintain corporate collaborations, as well as the\nability of BioLineRx's collaborators to execute on their development and\ncommercialization plans; BioLineRx's ability to integrate new therapeutic\ncandidates and new personnel, as well as new collaborations; the\ninterpretation of the properties and characteristics of BioLineRx's\ntherapeutic candidates and of the results obtained with its therapeutic\ncandidates in preclinical studies or clinical trials; the implementation of\nBioLineRx's business model and strategic plans for its business and\ntherapeutic candidates; the scope of protection that BioLineRx's is able to\nestablish and maintain for intellectual property rights covering its\ntherapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; estimates of\nBioLineRx's expenses, future revenues, capital requirements and its need for\nand ability to access sufficient additional financing; risks related to\nchanges in healthcare laws, rules and regulations in the United States or\nelsewhere; competitive companies, technologies and BioLineRx's industry;\nBioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements\nas to the impact of the political and security situation in Israel on\nBioLineRx's business which may exacerbate the magnitude of the factors\ndiscussed above. These and other factors are more fully discussed in the \"Risk\nFactors\" section of BioLineRx's most recent annual report on Form 20-F filed\nwith the Securities and Exchange Commission on March 23, 2026. In addition,\nany forward-looking statements represent BioLineRx's views only as of the date\nof this release and should not be relied upon as representing its views as of\nany subsequent date. BioLineRx does not assume any obligation to update any\nforward-looking statements unless required by law.\n\nContacts:\n\nUnited States\nChuck Padala\nLifeSci Advisors, LLC\nIR@biolinerx.com (mailto:IR@biolinerx.com)\n\nIsrael\nMoran Meir\nLifeSci Advisors, LLC\nmoran@lifesciadvisors.com (mailto:moran@lifesciadvisors.com)\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION\n\n(UNAUDITED)\n\n December 31, June 30,\n 2025 2026\n in USD thousands\n Assets\n CURRENT ASSETS\n Cash and cash equivalents 3,250 4,627\n Short-term bank deposits 17,626 8,451\n Prepaid expenses 201 376\n Other receivables 456 728\n Inventory 2,148 2,167\n Total current assets 23,681 16,349\n\n NON-CURRENT ASSETS\n Property and equipment, net 160 130\n Right-of-use assets, net 696 673\n Intangible assets, net 16,368 16,328\n Total non-current assets 17,224 17,131\n Total assets 40,905 33,480\n\n Liabilities and equity\n CURRENT LIABILITIES\n Current maturities of long-term loan 4,479 4,479\n Accounts payable and accruals:\n Trade 3,493 4,294\n Other 1,743 2,206\n Current maturities of lease liabilities 234 280\n Warrants 2,174 2,420\n Total current liabilities 12,123 13,679\n\n NON-CURRENT LIABILITIES\n Long-term loan, net of current maturities 4,460 2,220\n Lease liabilities 977 962\n Total non-current liabilities 5,437 3,182\n\n COMMITMENTS AND CONTINGENT LIABILITIES\n Total liabilities 17,560 16,861\n\n EQUITY\n Equity attributable to owners of the Company:\n Ordinary shares 73,428 73,776\n Share premium 327,584 327,928\n Warrants 3,686 3,686\n Capital reserve 15,916 15,425\n Other comprehensive loss (1,416) (1,416)\n Accumulated deficit (401,002) (405,629)\n Total equity attributable to owners of the Company 18,196 13,770\n Non-controlling 5,149 2,849\n interest\n Total equity 23,345 16,619\n Total liabilities and equity 40,905 33,480\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)\n\n(UNAUDITED)\n\n Three months ended June 30, Six months ended June 30,\n 2025 2026 2025 2026\n in USD thousands in USD thousands\n\n ROYALTY REVENUES 304 294 559 771\n COST OF REVENUES (72) (59) (106) (154)\n GROSS PROFIT 232 235 453 617\n RESEARCH AND DEVELOPMENT EXPENSES (2,326) (2,943) (3,949) (5,471)\n GENERAL AND ADMINISTRATIVE EXPENSES (209) (865) (1,198) (1,723)\n OPERATING LOSS (2,303) (3,573) (4,694) (6,577)\n NON-OPERATING INCOME (EXPENSES), NET (1,851) (690) 5,793 (232)\n FINANCIAL INCOME 490 132 784 340\n FINANCIAL EXPENSES (276) (208) (696) (458)\n\n NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (3,940) (4,339) 1,187 (6,927)\n\n ATTRIBUTION OF NET INCOME (LOSS) AND\n COMPREHENSIVE INCOME (LOSS)\n To owners of the Company (3,940) (3,026) 1,187 (4,627)\n To non-controlling interests - (1,313) - (2,300)\n (3,940) (4,339) 1,187 (6,927)\n\n in USD in USD\n EARNINGS (LOSS) PER ORDINARY SHARE – BASIC AND (0.00) (0.00) 0.00 (0.00)\n DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY\n\n WEIGHTED AVERAGE NUMBER OF SHARES USED IN 2,369,687,536 2,664,807,584 2,294,127,662 2,662,530,811\n CALCULATION OF BASIC AND DILUTED EARNINGS\n (LOSS) PER ORDINARY SHARE\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY\n\n(UNAUDITED)\n\n Equity attributable to owners of the Company\n Ordinary shares Share Warrants Capital Other Accumulated Non- Total\n premium reserve comprehensive deficit controlling\n loss interest\n in shares 000's in USD thousands\n BALANCE AT JANUARY 1, 2025 1,336,670 38,097 353,693 5,367 17,547 (1,416) (399,827) - 13,461\n CHANGES FOR SIX MONTHS\n ENDED JUNE 30, 2025:\n Issuance of share capital, pre-funded 925,137 25,664 (20,988) 501 - - - - 5,177\n warrants and warrants, net\n Pre-funded warrants exercised 295,804 8,058 (5,876) (2,182) - - - - -\n Employee stock options expired - - 646 - (646) - - - -\n Share-based compensation - - - - 247 - - - 247\n Comprehensive income for the period - - - - - - 1,187 - 1,187\n BALANCE AT JUNE 30, 2025 2,557,611 71,819 327,475 3,686 17,148 (1,416) (398,640) - 20,072\n\n Equity attributable to owners of the Company\n Ordinary shares Share Warrants Capital Other Accumulated Non- Total\n premium reserve comprehensive deficit controlling\n loss interest\n in shares 000's in USD thousands\n BALANCE AT JANUARY 1, 2026 2,610,814 73,428 327,584 3,686 15,916 (1,416) (401,002) 5,149 23,345\n CHANGES FOR SIX MONTHS\n ENDED JUNE 30, 2026:\n Issuance of share capital 10,163 348 (304) - - - - - 44\n Employee stock options expired - - 648 - (648) - - - -\n Share-based compensation - - - - 157 - - - 157\n Comprehensive loss for the period - - - - - - (4,627) (2,300) (6,927)\n BALANCE AT JUNE 30, 2026 2,620,977 73,776 327,928 3,686 15,425 (1,416) (405,629) 2,849 16,619\n\n \n\n \n BioLineRx Ltd.\n\nCONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS\n\n(UNAUDITED)\n\n Six months ended June 30,\n 2025 2026\n in USD thousands\n CASH FLOWS - OPERATING ACTIVITIES\n Comprehensive income (loss) for the period 1,187 (6,927)\n Adjustments required to reflect net cash used in operating activities (3,955) 1,430\n (see appendix below)\n Net cash used in operating activities (2,768) (5,497)\n\n CASH FLOWS - INVESTING ACTIVITIES\n Investments in short-term deposits (24,818) (7,663)\n Maturities of short-term deposits 12,926 16,714\n Proceeds from sale of property and equipment 11 -\n Net cash provided by (used in) investing activities (11,881) 9,051\n\n CASH FLOWS - FINANCING ACTIVITIES\n Issuance of share capital and warrants, net of issuance costs 13,554 44\n Repayments of loan (2,240) (2,240)\n Repayments of lease liabilities (262) (124)\n Net cash provided by (used in) financing activities 11,052 (2,320)\n\n INCREASE )DECREASE( IN CASH AND CASH EQUIVALENTS (3,597) 1,234\n CASH AND CASH EQUIVALENTS - BEGINNING 10,436 3,250\n\n  OF PERIOD\n EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS 350 143\n CASH AND CASH EQUIVALENTS - END OF PERIOD 7,189 4,627\n\n \n\n \n\n BioLineRx Ltd.\n\nAPPENDIX TO CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS\n\n(UNAUDITED)\n\n Six months ended June 30,\n 2025 2026\n in USD thousands\n APPENDIX\n\n Adjustments required to reflect net cash used in operating\n activities:\n Income and expenses not involving cash flows:\n Depreciation and amortization 341 166\n Exchange differences on cash and cash equivalents (350) (143)\n Fair value adjustments of warrants (6,410) 246\n Share-based compensation 247 157\n Interest and exchange differences on short-term deposits 48 124\n Warrant issuance costs 702 -\n Exchange differences on lease liabilities 110 82\n (5,312) 632\n\n Changes in operating asset and liability items:\n Decrease in trade receivables 2,398 -\n Decrease (increase) in prepaid expenses and other receivables 1,146 (447)\n Decrease (increase) in inventory 295 (19)\n Increase (decrease) in accounts payable and accruals (2,482) 1,264\n 1,357 798\n (3,955) 1,430\n\n Supplemental information on interest received in cash 583 463\n Supplemental information on interest paid in cash 694 467\n Supplemental information on non-cash transactions:\n Changes in right-of-use asset and lease liabilities 45 73\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html\n(https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html)\n\nSOURCE BioLineRx Ltd.\n\n\n\n+972-8-6429100\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1457856/BioLineRx-Ltd-Logo.jpg?id=OA2919214\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-31T11:00:04.502996715Z","server_sent_at_ms":1788174004502},"received_at":"2026-08-31T11:00:04.563Z","source_url":"https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html"},"analysis":{"id":"119890","press_release_id":"130986","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["cash runway extends only into first half of 2027","company announced a small dilutive offering of $3.75 million","G&A expenses increased 313.9% YoY due to reversal of prior period provision"],"eventType":"earnings","narrative":"BioLineRx reported Q2 2026 revenue of $0.3 million with a net loss of $4.3 million, ending the quarter with $13.1 million in cash to fund operations into the first half of 2027.\n\nThe company announced positive preclinical data for its lead asset GLIX1, showing potent antitumor activity in TMZ-resistant glioblastoma models and strong synergy with PARP inhibitors in ovarian cancer models.\n\nManagement is advancing the Phase 1/2a GBM trial, with the second cohort dosing and the third expected to start in September, while simultaneously planning an ovarian cancer arm for the Phase 2a expansion.\n\nOn August 27, 2026, the company entered into a definitive agreement for a public offering with gross proceeds of $3.75 million to bolster its cash position.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Positive GLIX1 preclinical data de-risks clinical pathway, but runway and small offering remain focus."},"keyFigures":{"eps":0,"revenue":294000,"guidance":"cash runway guidance into the first half of 2027","revenueYoy":"-3.3%","dealValueUsd":3750000,"customDimensions":{"net_loss":4339000,"ga_expenses":865000,"rd_expenses":2943000,"cash_balance":13100000,"aphexda_sales":1600000}},"quotedText":"Together, these developments keep GLIX1 on track in glioblastoma while extending its reach into additional tumor types where new treatment options are desperately needed.","namedEntities":{"people":[{"name":"Philip Serlin","role":"Chief Executive Officer"},{"name":"Dr. Alexandra Miller","role":"Principal Investigator, NYU Langone Health"},{"name":"Dr. Roger Stupp","role":"Principal Investigator, Northwestern University"},{"name":"Dr. Ditte Primdahl","role":"Principal Investigator, Northwestern University"},{"name":"Dr. Patrick Grogan","role":"Principal Investigator, Moffitt Cancer Center"}],"products":["GLIX1","APHEXDA","motixafortide","cemiplimab","gemcitabine","nab-paclitaxel","olaparib","cisplatin","temozolomide"],"companies":[{"name":"BioLineRx Ltd.","ticker":"BLRX"},{"name":"Hemispherian AS","relationship":"collaborator"},{"name":"Regeneron","relationship":"trial supporter"},{"name":"Columbia University","relationship":"trial leader"},{"name":"Ayrmid Ltd.","relationship":"commercialization partner"},{"name":"Gloria Biosciences","relationship":"commercialization partner"}],"dollarAmounts":[{"amount":"$13.1 million","context":"cash balance as of June 30, 2026"},{"amount":"$3.75 million","context":"gross proceeds of offering"},{"amount":"$1.6 million","context":"APHEXDA sales for Q2 2026"},{"amount":"$0.3 million","context":"royalty revenue for Q2 2026"},{"amount":"$2.9 million","context":"R&D expenses for Q2 2026"},{"amount":"$0.9 million","context":"G&A expenses for Q2 2026"},{"amount":"$4.3 million","context":"Net loss for Q2 2026"}]},"materialImpact":{"score":3,"reasoning":"Positive clinical updates for GLIX1 (new PDX data, PARPi synergy, cohort advancement) are offset by minimal cash runway into H1 2027 and a small dilutive offering. Earnings are routine for a clinical-stage biotech with negligible revenue."},"tickerRelevance":{"others":[],"primary":"BLRX"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":["operations_update","offering"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"clinical-update-plus-earnings","sectorWeight":"Biotech","cashRunwayRisk":"high"}},"event_type":"earnings","event_type_secondary":["operations_update","offering"],"sentiment":"mixed","material_impact_score":3,"narrative":"BioLineRx reported Q2 2026 revenue of $0.3 million with a net loss of $4.3 million, ending the quarter with $13.1 million in cash to fund operations into the first half of 2027.\n\nThe company announced positive preclinical data for its lead asset GLIX1, showing potent antitumor activity in TMZ-resistant glioblastoma models and strong synergy with PARP inhibitors in ovarian cancer models.\n\nManagement is advancing the Phase 1/2a GBM trial, with the second cohort dosing and the third expected to start in September, while simultaneously planning an ovarian cancer arm for the Phase 2a expansion.\n\nOn August 27, 2026, the company entered into a definitive agreement for a public offering with gross proceeds of $3.75 million to bolster its cash position.","key_figures":{"eps":0,"revenue":294000,"guidance":"cash runway guidance into the first half of 2027","revenueYoy":"-3.3%","dealValueUsd":3750000,"customDimensions":{"net_loss":4339000,"ga_expenses":865000,"rd_expenses":2943000,"cash_balance":13100000,"aphexda_sales":1600000}},"named_entities":{"people":[{"name":"Philip Serlin","role":"Chief Executive Officer"},{"name":"Dr. Alexandra Miller","role":"Principal Investigator, NYU Langone Health"},{"name":"Dr. Roger Stupp","role":"Principal Investigator, Northwestern University"},{"name":"Dr. Ditte Primdahl","role":"Principal Investigator, Northwestern University"},{"name":"Dr. Patrick Grogan","role":"Principal Investigator, Moffitt Cancer Center"}],"products":["GLIX1","APHEXDA","motixafortide","cemiplimab","gemcitabine","nab-paclitaxel","olaparib","cisplatin","temozolomide"],"companies":[{"name":"BioLineRx Ltd.","ticker":"BLRX"},{"name":"Hemispherian AS","relationship":"collaborator"},{"name":"Regeneron","relationship":"trial supporter"},{"name":"Columbia University","relationship":"trial leader"},{"name":"Ayrmid Ltd.","relationship":"commercialization partner"},{"name":"Gloria Biosciences","relationship":"commercialization partner"}],"dollarAmounts":[{"amount":"$13.1 million","context":"cash balance as of June 30, 2026"},{"amount":"$3.75 million","context":"gross proceeds of offering"},{"amount":"$1.6 million","context":"APHEXDA sales for Q2 2026"},{"amount":"$0.3 million","context":"royalty revenue for Q2 2026"},{"amount":"$2.9 million","context":"R&D expenses for Q2 2026"},{"amount":"$0.9 million","context":"G&A expenses for Q2 2026"},{"amount":"$4.3 million","context":"Net loss for Q2 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T11:19:17.706Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"clinical-update-plus-earnings","sectorWeight":"Biotech","cashRunwayRisk":"high"}},"durationMs":74306,"modelName":"glm-4.7"}}